Reconstitute with 20mM Tris and 150mM NaCl to 0.1-1.0mg/ml. Do not vortex. Lyophilized from 20mM Tris, 150mM NaCl, 1mM EDTA, 1mM DTT, 0.01% SKL, 5% Trehalose, ProClin 300.
Expression System:
E. coli
Formulierung:
Lyophilized powder
Sequenz:
N-terminal His-Tag, Val30~leu268 (NP_001071117.1)
Anwendungsbeschreibung:
Elastase 4 (ELA4) is a member of the peptidase S1 family. The encoded protein is a serum calcium-decreasing factor that has chymotrypsin-like protease activity. It regulates activation and degradation of trypsinogens and procarboxypeptidases by targeting specific cleavage sites within their zymogen precursors. Has chymotrypsin-type protease activity and hypocalcemic activity. Besides, Plasminogen Activator, Urokinase Receptor (uPAR) has been identified as an interactor of ELA4, thus a binding ELISA assay was conducted to detect the interaction of recombinant rat ELA4 and recombinant rat uPAR. Briefly, ELA4 were diluted serially in PBS, with 0.01% BSA (pH 7.4). Duplicate samples of 100 µl were then transferred to uPAR-coated microtiter wells and incubated for 2h at 37C. Wells were washed with PBST and incubated for 1h with anti-ELA4 pAb, then aspirated and washed 3 times. After incubation with HRP labelled secondary antibody, wells were aspirated and washed 3 times. With the addition of substrate solution, wells were incubated 15-25 minutes at 37C. Finally, add 50 µl stop solution to the wells and read at 450nm immediately. The binding activity of of ELA4 and uPAR was in a dose dependent manner.
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
